BL Pharmtech Corp. (KOSDAQ:065170)
South Korea
· Delayed Price · Currency is KRW 2,420.00
-65.00 (-2.62%)
At close: Apr 28, 2026
BL Pharmtech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 6,506 | 8,806 | 24,525 | 22,523 | 84,440 | Upgrade
|
| Other Revenue | -0 | -0 | - | - | -0 | Upgrade
|
| Revenue | 6,506 | 8,806 | 24,525 | 22,523 | 84,440 | Upgrade
|
| Revenue Growth (YoY) | -26.12% | -64.10% | 8.89% | -73.33% | 28.54% | Upgrade
|
| Cost of Revenue | 2,814 | 2,885 | 10,964 | 9,801 | 63,367 | Upgrade
|
| Gross Profit | 3,692 | 5,921 | 13,561 | 12,722 | 21,073 | Upgrade
|
| Selling, General & Admin | 5,961 | 8,287 | 19,473 | 16,825 | 24,014 | Upgrade
|
| Amortization of Goodwill & Intangibles | 148.75 | 341.79 | 338.08 | - | - | Upgrade
|
| Operating Expenses | 5,724 | 10,265 | 20,680 | 17,510 | 24,668 | Upgrade
|
| Operating Income | -2,032 | -4,345 | -7,119 | -4,789 | -3,595 | Upgrade
|
| Interest Expense | -899.73 | -829.33 | -1,573 | -2,206 | -2,591 | Upgrade
|
| Interest & Investment Income | 259.12 | 302.46 | 51.42 | 131.12 | 103 | Upgrade
|
| Earnings From Equity Investments | -10,651 | -1,668 | -469.42 | -358.97 | -51.29 | Upgrade
|
| Currency Exchange Gain (Loss) | -31.07 | 24.38 | 9.56 | 64.6 | -374.37 | Upgrade
|
| Other Non Operating Income (Expenses) | -27.96 | 1,638 | -2,854 | -2,079 | -1,012 | Upgrade
|
| EBT Excluding Unusual Items | -13,383 | -4,877 | -11,955 | -9,237 | -7,521 | Upgrade
|
| Gain (Loss) on Sale of Investments | -3,262 | -17.56 | - | 283.8 | 67.12 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.34 | 78.66 | 53.01 | - | 3,084 | Upgrade
|
| Asset Writedown | - | -950 | -2,900 | -5,151 | -16,238 | Upgrade
|
| Other Unusual Items | -138.28 | - | 944.78 | 31.04 | 38.48 | Upgrade
|
| Pretax Income | -16,781 | -5,766 | -13,856 | -14,073 | -20,570 | Upgrade
|
| Income Tax Expense | 5.94 | -49.36 | -46.23 | 363.26 | -462.69 | Upgrade
|
| Earnings From Continuing Operations | -16,787 | -5,717 | -13,810 | -14,437 | -20,107 | Upgrade
|
| Earnings From Discontinued Operations | - | - | 13,952 | 787.1 | - | Upgrade
|
| Net Income to Company | -16,787 | -5,717 | 141.63 | -13,649 | -20,107 | Upgrade
|
| Minority Interest in Earnings | 9.63 | 10.4 | -290.47 | -253.65 | -104.49 | Upgrade
|
| Net Income | -16,778 | -5,706 | -148.85 | -13,903 | -20,211 | Upgrade
|
| Net Income to Common | -16,778 | -5,706 | -148.85 | -13,903 | -20,211 | Upgrade
|
| Shares Outstanding (Basic) | 27 | 27 | 27 | 27 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 27 | 27 | 27 | 27 | 26 | Upgrade
|
| Shares Change (YoY) | 0.03% | -0.09% | - | 1.33% | 18.44% | Upgrade
|
| EPS (Basic) | -629.00 | -214.00 | -5.58 | -520.90 | -767.32 | Upgrade
|
| EPS (Diluted) | -629.00 | -214.00 | -5.58 | -520.90 | -767.32 | Upgrade
|
| Free Cash Flow | -283.76 | -4,203 | 7,680 | -12,706 | 2,510 | Upgrade
|
| Free Cash Flow Per Share | -10.64 | -157.64 | 287.73 | -476.04 | 95.28 | Upgrade
|
| Gross Margin | 56.74% | 67.24% | 55.30% | 56.48% | 24.96% | Upgrade
|
| Operating Margin | -31.24% | -49.34% | -29.03% | -21.26% | -4.26% | Upgrade
|
| Profit Margin | -257.89% | -64.81% | -0.61% | -61.73% | -23.94% | Upgrade
|
| Free Cash Flow Margin | -4.36% | -47.74% | 31.31% | -56.41% | 2.97% | Upgrade
|
| EBITDA | -1,476 | -3,492 | -6,271 | -3,888 | -146.75 | Upgrade
|
| EBITDA Margin | -22.69% | -39.66% | -25.57% | -17.26% | -0.17% | Upgrade
|
| D&A For EBITDA | 556.32 | 852.35 | 848.1 | 900.55 | 3,448 | Upgrade
|
| EBIT | -2,032 | -4,345 | -7,119 | -4,789 | -3,595 | Upgrade
|
| EBIT Margin | -31.24% | -49.34% | -29.03% | -21.26% | -4.26% | Upgrade
|
| Advertising Expenses | 766.18 | 1,643 | 3,675 | 2,206 | 2,535 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.